Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 3 2Phase 1 2Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 3Endocrine 3NET 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Breast 1

Conditions

Neuroendocrine Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Everolimus 10lutetium Lu 177 dotatate 7Magnetic Resonance Spectroscopy 7pasireotide 4Specimen Handling 3Positron Emission Tomography Computed Tomography 3Nivolumab 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3(177)Lu-DOTA-EB-TATE 3olaparib 2gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Lutetium-177 2Ipilimumab 2FAPI-46 2veliparib 1vandetanib 1trifluridine tipiracil drug combination 1toripalimab 1tislelizumab 1talazoparib 1surufatinib 1romidepsin 1peposertib 1pembrolizumab 1pelcitoclax 1pegfilgrastim 1lanreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lutetium-177 × NET × Clear all
NCT05249114 2026-04-13

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Providence Health & Services

Phase 1 Active not recruiting
6 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT07150546 2026-03-02

Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.

Emory University

Phase 1 Recruiting
15 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡